How often eyelids are affected in adults with atopic dermatitis
Official title: Frequency of Palpebral Involvement in Adult Atopic Dermatitis, in a Cohort of Patients From Lille and Rouen (France) ; a Multicenter Prospective Study
Run by University Hospital, Lille · NCT04826744 · Data updated 2026-11-12
This project will see how often adults with atopic dermatitis have eyelid (palpebral) involvement and will try patch-testing to look for possible allergic causes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 550 (estimated) |
| Sponsor | University Hospital, Lille Academic / other |
| Locations | 2 sites (Lille and 1 other locations) |
| Status | Recruiting |
| Started | September 1, 2021 |
| Main results expected | June 2026 |
| Study ends | June 2026 |
| Registry record updated | December 23, 2025 |
| Trial ID | NCT04826744 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with atopic dermatitis by revised Hanifin and Rajka criteria who can give oral consent and have valid social insurance are ideal candidates.
✕Probably not a fit
People under 18, those who are pregnant or breastfeeding, patients with uncontrolled asthma, or those without social insurance are excluded and would not be eligible to participate or benefit from this observational protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational study enrolling adults diagnosed with atopic dermatitis using the Hanifin and Rajka criteria to document how frequently the eyelids are involved. Participants will have a standard dermatology consultation and may undergo allergy-focused evaluations such as patch-testing as part of the protocol. The study will also record associated eye conditions (for example conjunctivitis or keratoconus) and collect clinical data to better describe the palpebral presentation. No investigational drugs are given; the aim is to characterize prevalence and possible allergic contributors to eyelid disease in atopic dermatitis.
Why it matters
Potential benefit: If successful, the study could help clinicians recognize eyelid involvement earlier and guide more targeted allergy testing and management for affected patients.
How similar studies have gone: Previous publications estimate palpebral involvement at about 20% but prospective allergological (patch-test) studies in this specific patient group are essentially lacking, making this approach relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Atopic Dermatitis according to the revised Hanifin and Rakja criteria (UK Working Party) * Oral consent * Valid social insurance Exclusion Criteria: * Personal history of uncontrolled asthma * No social insurance * Protective measures * Age under 18 * Pregnancy or breast-feeding
Where it's running
-
Hop Claude Huriez Chu Lille
Lille, France Recruiting -
Hopital Charles Nicolle Chu Rouen
Rouen, France Recruiting
Study contacts
- Principal investigator: Delphine Staumont-Salle, MD,PhD — University Hospital, Lille
- Study coordinator: Delphine Staumont-Salle, MD,PhD
- Email: delphine.salle@chru-lille.fr
- Phone: 0320445962
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults
A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.
-
Nocturnal ScratchSense ring: test of automatic scratch detection in adults with itchy skin
This study tests whether the Replior ScratchSense ring can accurately detect and measure nighttime scratching in adults with itchy skin conditions.
-
ADBest TREAT Registry for adults with atopic dermatitis
A registry in Germany is collecting real-world data from adults with atopic dermatitis to see how treatments are used and how the disease affects quality of life.
-
How lebrikizumab affects the skin microbiome and mycobiome in adults with atopic dermatitis
This study looks at whether lebrikizumab changes the skin bacteria, fungi, and specifically Staphylococcus species, in adults with moderate-to-severe atopic dermatitis.
-
QX-4533 safety study in healthy volunteers and people with moderate-to-severe atopic dermatitis
This study tests the safety and tolerability of QX-4533, given as a pill, in healthy adults and in patients with moderate-to-severe atopic dermatitis to see how the drug behaves in the body and what side effects may occur.
-
Tilrekimig for moderate-to-severe eczema in teens and adults
A 52-week study will test tilrekimig against dupilumab and a placebo to see if it helps people 12 and older with moderate-to-severe atopic dermatitis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.